Biotech Values

[mcbio]

PLX: PRX102 ERT for Fabry, currently in ph1/2. With efficacy problem from Amigal monotherapy trial, Replagal not getting approved in US, it presents a great opportunity for PRX102.

Thanks. PLX Web site says we should have this data fairly soon (http://www.protalix.com/product-development/prx-102.asp ). It does say it's primarily for safety but does note that "secondary outcome measures may reveal some efficacy." How big of an inflection point do you think this will be for the drug and shares?